(Reuters) - Amgen Inc on Monday reported higher-than-expected third quarter profit and revenue, helped by strong demand for its white blood cell booster, Neulasta, and increased sales of newer drugs, and the company raised it full-year forecast.
The world's largest biotechnology company's net profit fell for the quarter primarily due to a $376 million charge related to restructuring moves it announced in late July.
Amgen said it now expects 2014 adjusted earnings of $8.45 to $8.55 per share, up from the boosted forecast it provided in July of $8.20 to $8.40 per share. The company expects full-year revenue of $19.8 billion to $20 billion. It previously forecast $19.5 billion to $19.7 billion.
Amen posted a net profit of $1.24 billion, or $1.61 per share, down from a profit of $1.37 billion, or $1.79 per share, a year ago.
Excluding items, Amgen earned $2.30 per share. Analysts on average expected $2.11, according to Thomson Reuters I/B/E/S.
(Reporting by Bill Berkrot; Editing by Chris Reese)
Relacionados
- Liberbank amortiza una emisión de obligaciones convertibles contingentes por 124 millones suscrita por el frob
- Santamaría: "A los ciudadanos no se les puede imponer obligaciones que el presidente de la Generalitat no asume"
- Presidencia congela subvenciones a partidos para las elecciones y ajusta los gastos para asumir otras obligaciones
- Economía/Finanzas.- Liberbank ampliará capital por un 0,014% para responder a peticiones de conversión de obligaciones
- El SPE propone para este jueves una charla sobre los derechos y obligaciones de los autónomos con la Seguridad Social
